Related references
Note: Only part of the references are listed.Ovarian Cancer Statistics, 2018
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
Joyce F. Liu et al.
CLINICAL CANCER RESEARCH (2017)
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives
Jole Ventriglia et al.
CANCER TREATMENT REVIEWS (2017)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Adoptive immunotherapy against ovarian cancer
Gloria Mittica et al.
JOURNAL OF OVARIAN RESEARCH (2016)
Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumors
Ulrich Jarry et al.
ONCOIMMUNOLOGY (2016)
Molecules and mechanisms implicated in the peculiar antigenic activation process of human Vγ9Vδ2T cells
Christelle Harly et al.
FRONTIERS IN IMMUNOLOGY (2015)
γδ T Cells: First Line of Defense and Beyond
Yueh-hsiu Chien et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer
S. John Weroha et al.
CLINICAL CANCER RESEARCH (2014)
Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer
Pierre-Emmanuel Colombo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
First In-Mouse Development and Application of a Surgically Relevant Xenograft Model of Ovarian Carcinoma
Oystein Helland et al.
PLOS ONE (2014)
What lessons can be learned from γδ T cell-based cancer immunotherapy trials?
Jean-Jacques Fournie et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2013)
Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset
Christelle Harly et al.
BLOOD (2012)
Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes
Dongmei Lai et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: Implications for immunotherapy
Vincent Lavoue et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Anticancer Properties of Zoledronic Acid
Jonathan Green et al.
CANCER INVESTIGATION (2010)
Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes
Juan R. Cubillos-Ruiz et al.
CELL CYCLE (2010)
Zoledronic acid - A review of its use in the management of bone metastases of malignancy
Sohita Dhillon et al.
DRUGS (2008)
Self/non-self discrimination by human γδ T cells:: simple solutions for a complex issue?
Aurelie Thedrez et al.
IMMUNOLOGICAL REVIEWS (2007)
Involvement of CD166 in the activation of human γδT cells by tumor cells sensitized with nonpeptide antigens
Yu Kato et al.
JOURNAL OF IMMUNOLOGY (2006)
Share Paper
